Treatment for hemophilia: recombinant versus plasma-derived coagulation factors - controversy and debate forever? An ethical medical challenge?

Expert Rev Hematol. 2013 Oct;6(5):489-92. doi: 10.1586/17474086.2013.834798. Epub 2013 Oct 2.

Authors

Antonio Liras¹, Rebecca García-Trenchard

Affiliation

¹ Department of Physiology, Biological Sciences School, Complutense University of Madrid, Cell Therapy and Regenerative Medicine Unit, La Paz University Hospital Health Research Institute-IdiPAZ, Madrid, 28040, Spain.

PMID: 24083561
DOI: 10.1586/17474086.2013.834798

No abstract available

Publication types

Editorial
Research Support, Non-U.S. Gov't

MeSH terms

Blood Coagulation Factors / adverse effects
Blood Coagulation Factors / therapeutic use
Hemophilia A / therapy*
Hemophilia B / therapy*
Humans
Recombinant Proteins / adverse effects
Recombinant Proteins / therapeutic use

Substances

Blood Coagulation Factors
Recombinant Proteins